Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 170

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 170
---
 stockholders. Further, pursuant to Delaware law a director or officer may not be exculpated for:

| ● | any                                                                                                       
 breach of his or her duty of loyalty to us or our stockholders;                                           |
| ● | acts                                                                                                      
 or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; and |
| ● | any                                                                                                       
 transaction from which the director or officer derived an improper personal benefit.                      |

These limitations of liability do not apply to liabilities arising under the federal or state securities laws and do not affect the availability of equitable remedies such as injunctive relief or rescission.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

At present, there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

| 81 |

<div align='center'>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>

We are offering 7,014,028 shares of our Common Stock at an assumed combined public offering price of $0.499 per share and accompanying May 2025 Warrant (the last reported sale price of our Common Stock on Nasdaq on April 25, 2025). We are also offering Pre-Funded Warrants to those purchasers whose purchase of shares of our Common Stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of Common Stock following the consummation of this offering in lieu of the shares of Common Stock that would result in such excess ownership. For each Pre-Funded Warrant sold, the number of shares of Common Stock sold will be reduced on a one-for-one basis. Each share of our Common Stock or Pre-Funded Warrant is being sold together with one May 2025 Warrant to purchase one and one-half share of Common Stock. The shares of Common Stock and/or Pre-Funded Warrants and the accompanying May 2025 Warrants can only be purchased together in this offering but will be issued separately and will be immediately separ